Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT06942767 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: QLS31905 for Injection
DRUG: QL2107 Injection
DRUG: Oxaliplatin Injection
DRUG: Capecitabine Tablets

Sponsor

Qilu Pharmaceutical Co., Ltd.